Nov 7, 2026, 17:03
Nicole Dobkin: Survey Reveals Major Disconnect Between Access to Apheresis and Patient Utilization in Sickle Cell Care
Nicole Dobkin, Global PR Manager at Terumo Blood and Cell Technologies, shared a post on LinkedIn:
“‘A recent survey of 100 providers who manage at least one patient with Sickle Cell disease found that 91% said their patients had access to the treatment, but only 3% of patients had actually undergone the procedure.’
Aaron Haubner, Terumo Blood and Cell Technologies:
What we found was the treating physicians reported a relatively strong familiarity with transfusion care and a relatively strong knowledge of the guidelines.
Then we asked about apheresis services, and 91% said there was widespread availability of apheresis services within their hospital system or facility.
And yet, then we see this drop-off.”
Stay updated with Hemostasis Today.
-
Nov 7, 2026, 16:58Muhammad Essa: Comparing Indobufen and Aspirin in Acute Ischemic Stroke
-
Nov 7, 2026, 16:42Inderpaul Birdi: Warfarin or Newer Blood Thinners?
-
Nov 7, 2026, 16:31Arwa Z. Al-Riyami: EMR Transfusion Medicine Featured in October 2026 Issue of ISBT Transfusion Today
-
Nov 7, 2026, 16:31Rafael Gomes: Is Dual Antiplatelet Therapy Still Necessary After LAAO?
-
Nov 7, 2026, 16:15Mazyar Shadman: Novel BTK Inhibitors and DOACs A Multicenter Study of Bleeding Risk
-
Nov 7, 2026, 15:54Hassan Raza: Beyond the 100 Minus Age Rule in Bone Marrow Cellularity
-
Nov 7, 2026, 15:42Andrew Zapfel։ Advancing Sickle Cell Disease Care Through Training, Advocacy and Collaboration
-
Nov 7, 2026, 15:34Salih Ehsan: Iron Deficiency Beyond Conventional Ferritin Cutoffs
-
Nov 7, 2026, 15:21Shamee Shastry: Improving the Reliability and Reproducibility of the Monocyte Monolayer Assay